PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
暂无分享,去创建一个
L. Sequist | E. Smit | E. Felip | F. Barlesi | L. Gandhi | B. Besse | S. Bailey | E. Garon | E. Carcereny | H. Groen | D-W. Kim | S. Kim | M. Akimov | Emin Avşar | W. Ofosu-Appiah | D. Kim